The use of risperidone among individuals with mental retardation: Clinically supported or not?

Research in Developmental Disabilities

Volumn 26, Issue 3, 2005, Pages 203-218

  Singh, Ashvind N ^a   Matson, Johnny L ^a   Cooper, Christopher L ^a   Dixon, Dennis ^a   Sturmey, Peter ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Antipsychotic medications; Mental retardation; Risperidone

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; THIORIDAZINE;

AGITATION; AKATHISIA; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DROWSINESS; DRUG EFFICACY; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERSALIVATION; LETHARGY; MENTAL DEFICIENCY; MOTOR DYSFUNCTION; NAUSEA; NOCTURNAL ENURESIS; OCULOGYRIC CRISIS; PARKINSONISM; PRESCRIPTION; PREVALENCE; REVIEW; SOMNOLENCE; TREMOR; WEIGHT GAIN;

EID: 12844266858     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2004.07.001     Document Type: Article

References (33)

1. M.G. Aman, G. De Smedt, A. Derivan, B. Lyons, R.L. Findling The Risperidone Disruptive Behavior Study Group Double-blind, placebo controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence American Journal of Psychiatry 159 2002 1337 1346
2. M.G. Aman, and A. Madrid Atypical antipsychotics in persons with developmental disabilities Mental Retardation and Developmental Disabilities Research Review 5 1999 253 263
3. M.G. Aman, and N.N. Singh The usefulness of thioridazine for treating childhood disorders: Fact or folklore? American Journal of Mental Deficiency 84 1980 331 338
4. M.G. Aman, and N.N. Singh Psychopharmacological intervention J.L. Matson J.A. Mulick Handbook of mental retardation 2nd ed. 1991 Pergamon Press New York 327 372
5. S.W. Bisconer, L.F. Sine, and X. Zhang Prevalence and patterns of psychotropic medication use by adults with mental retardation living in community settings Journal of Developmental and Physical Disabilities 8 1996 291 311
6. J.K. Buitelaar Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior Journal of Child and Adolescent Psychopharmacology 10 2000 19 26
7. J.K. Buitelaar, R. van der Gaag, P. Cohen-Kettenis, and C.T.M. Melman A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities Journal of Clinical Psychiatry 62 2001 239 248
8. S.A. Cohen, K. Ihrig, R.S. Lott, and J.M. Kerrick Risperidone for aggression and self-injurious behavior in adults with mental retardation Journal of Autism and Developmental Disorders 28 1998 229 233
9. R.J. Diamond Instant psychopharmacology 2nd ed. 2002 W.W. Norton & Company New York
10. R. Friedlander, S. Lazar, and J. Klancnik Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities Canadian Journal of Psychiatry 46 2001 741 745
11. A. Hardan, K. Johnson, C. Johnson, and B. Hrecznyj Case study: Risperidone treatment of children and adolescents with developmental disorders Journal of the American Academy of Child and Adolescent Psychiatry 35 1996 1551 1556
12. R.M. Hodapp, and E.M. Dykens Mental retardation (intellectual disabilities) E.J. Mash R.A. Barkley Child psychopathology 2nd ed. 2003 The Guilford Press NY 486 519
13. J. Intagliata, and M.A. Rinck Psychoactive drug use in public and community residential facilities for mentally retarded persons Psychopharmacology Bulletin 21 1985 268 278
14. B.U. Khan Risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults Journal of Autism and Developmental Disorders 27 1997 479 489
15. R.S. Lipman The use of psychopharmacological agents in residential facilities for the retarded F.J. Menolascino Psychiatric approaches to mental retardation 1970 Basic Books NY 387 398
16. R.S. Lott, J.M. Kerrick, and S.A. Cohen Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral distubance Psychopharmacology Bulletin 32 1996 721 729
17. N. Maneeton, S. Intaprasert, and M. Srisurapanont Journal of the Medical Association of Thailand 84 2001 893 896
18. J.L. Matson, J.W. Bamburg, E.A. Mayville, J. Pinkston, J. Bielecki, and D. Kuhn Psychopharmacology and mental retardation: A 10 year review (1990-1999) Research in Developmental Disabilities 21 2000 263 296
19. C.J. Mcdougle, J.P. Holmes, M.R. Bronson, G.M. Anderson, F.R. Volkmar, and L.H. Price Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study Journal of the American Academy of Child and Adolescent Psychiatry 36 1997 685 693
20. D. Natarajan, A.J. Martin, and D. Tesh Risperidone therapy in the control of behavioural disturbances in patients with learning disability Irish Journal of Psychological Medicine 14 1997 69 71
21. S.E. Purdon, W. Lit, A. Labelle, and B.D. Jones Risperidone in the treatment of pervasive developmental disorder Canadian Journal of Psychiatry 39 1994 400 405
22. S. Reiss M.G. Aman The international consensus handbook 1998 Nisonger Center, Ohio State University Columbus, OH
23. A.J. Rush, and A. Frances Expert consensus guideline series: Treatment of psychiatric and behavioral problems in mental retardation [Special issue] American Journal of Mental Retardation 105 2000
24. E.W. Simon, K.M. Blubaugh, and M. Pippidis Substituting traditional antipsychotics with risperidone for individuals with mental retardation Mental Retardation 34 1996 359 366
25. N.N. Singh, C.R. Ellis, and H. Wechsler Psychopharmacoepidemiology of mental retardation: 1966 to 1995 Journal of Child and Adolescent Psychopharmacology 7 1997 255 266
26. R. Snyder, A. Turgay, M.G. Aman, C. Binder, S. Fisman, A. Carroll The Risperidone Conduct Study Group Effects of risperidone on conduct disorders in children with subaverage IQ's Journal of the American Academy of Child and Adolescent Psychiatry 41 2002 1026 1036
27. R.L. Sprague, and J.S. Werry Methodology of psychopharmacological studies with the retarded N.R. Ellis International review of research in mental retardation 1971 Academic Press New York 147 219
28. A. Turgay, C. Binder, R. Snyder, and S. Fisman Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQ's Pediatrics 110 2002 e34
29. M. Van Bellinghen, and C. De Troch Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial Journal of Child and Adolescent Psychopharmacology 11 2001 5 13
30. R. Vanden Borre, R. Vermote, M. Buttiens, P. Thiry, G. Dierick, and J. Geutjens Risperidone as add-on therapy in behavioral disturbances in mental retardation: A double-blind placebo-controlled cross-over study Acta Psychiatry Scandinavia 87 1993 167 171
31. H. Williams, R. Clarke, N. Bouras, J. Martin, and G. Holt Use of the atypical antipsychotic olanzapine and risperidone in adults with intellectual disability Journal of Intellectual Disability Research 44 2000 164 169
32. A.T. Young, and J. Hawkins Psychotropic medication prescriptions: An analysis of the reasons people with mental retardation are prescribed psychotropic medication Journal of Developmental and Physical Disabilities 14 2002 129 142
33. J.R. Zarcone, J.A. Hellings, K. Crandall, R.M. Reese, J. Marquis, and K. Fleming Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures American Journal on Mental Retardation 106 2001 525 538